AI in Small Molecule Drug Discovery Webinar
The webinar titled "AI in Small Molecule Drug Discovery" scheduled for December 14th, 2022, at 14:00 GMT will explore the realistic impact of AI and machine learning in drug discovery by addressing past technology challenges, insights from related industries, and three essential strategies for successful AI implementation, emphasizing that while AI is not just hype, expectations must be managed as most AI-driven drug candidates remain in early development stages.
Despite the buzz around artificial intelligence (AI), most industry insiders know that the use of machine learning (ML) in drug discovery is nothing new. For more than a decade, researchers have used computational techniques for many purposes, such as finding hits, modeling drug-protein interactions, and predicting reaction rates.
What is new is the hype. As AI has taken off in other industries, countless start-ups have emerged promising to transform drug discovery and design with AI-based technologies. While a few “AI-native” candidates are in clinical trials, around 90% remain in discovery or preclinical development, so it will take years to see if the bets pay off. This begs the question: Is AI for drug discovery more hype than hope? Absolutely not. Do we need to adjust our expectations and position for success? Absolutely, yes.
In this webinar, we will discuss:
- Learnings from previous technology implementation challenges
- Learnings from adjacent industries
- Three Keys to Successful AI implementation
Event Details
- December 14th, 2022
- 14:00 GMT
- Online
Related
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
Scripps News America Tonight
Phil Mounteney, VP of Science and Technology at Dotmatics, explains in Scripps News America Tonight how Dotmatics Luma uses AI to transform scientific research and pharmaceutical drug discovery by accelerating innovation, lowering costs, and shortening time-to-market for modern laboratories.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
AI’s Quiet Revolution is Accelerating Drug Discovery, Education and More
The Fast Company article discusses how AI is quietly revolutionizing industries like drug discovery and education by enabling faster, more efficient solutions that address global challenges, with Dotmatics offering personalized demos of their Luma platform to showcase AI capabilities in scientific research.
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.